United States: First Amendment Protects Truthful Off-Label Speech By Drug Manufacturers

Last Updated: August 18 2015
Article by Brian P. Dunphy and Joanne S. Hawana

Pharmaceutical manufacturers have likely taken note of Amarin Pharma Inc.'s recent success in a pre-enforcement legal challenge against the Food and Drug Administration (FDA or the Agency). On August 7, 2015, Amarin obtained a preliminary injunction that prevents the Agency from bringing misbranding charges against the company for making truthful statements to doctors about off-label (unapproved) uses of the drug Vascepa® (icosapent ethyl). Amarin claimed that FDA's threat of initiating a misbranding action had a chilling effect on the company's ability to engage in constitutionally protected truthful speech, and from providing valuable information to physicians. This significant ruling from Judge Paul Engelmayer in the Southern District of New York represents the first time FDA has been enjoined on First Amendment grounds from prosecuting a drug manufacturer for misbranding based on the manufacturer's truthful marketing of its product.

In filing its complaint against FDA, Amarin sought protection for its speech "both at a general and a statement-specific level." At a general level, Amarin's First Amendment challenge alleges that FDA's threat of misbranding under provisions of the Federal Food, Drug and Cosmetic Act (FFDCA or the Act), 21 U.S.C., §§ 331(a) and 333(a)(1), restricted Amarin's speech. Based on United States v. Caronia – a 2012 decision from the Second Circuit, discussed previously on our blog, here and here, in which the conviction of a drug company sales representative was vacated because Caronia could not be convicted for on the basis of his truthful speech about off-label uses for a drug – the court broadly held that Amarin may engage in truthful and non-misleading speech promoting an off-label use of Vascepa, and that this speech may not form that basis of a prosecution for criminal misbranding. At the statement-specific level, the court also reviewed in great detail specific statements and disclosures for which Amarin sought comfort would not be the subject of a misbranding action.

Although the decision appears to provide some breathing room for manufacturers to make truthful off-label marketing statements under the FFDCA, the Amarin court also affirmed FDA's interests in ensuring the accuracy of information distributed by drug companies, as established by the Supreme Court in the 1980 Central Hudson decision. Specifically, governmental restrictions on truthful commercial speech must advance a substantial government interest, and they may not be more extensive than necessary to serve that interest.

Regulatory Background

Neither the FFDCA nor FDA's implementing regulations expressly prohibit the promotion or marketing of drugs for an off-label use. But FDA's longstanding position regarding off-label marketing by drug manufacturers derives from the statutory prohibition against the introduction of any "misbranded" drug into interstate commerce. The Act establishes that a drug is misbranded if its labeling does not include "adequate directions for use," and FDA regulations explain that this means directions for use must provide for the safe use of the drug for the purposes for which it is intended the manufacturer or distributor.

In prosecuting cases involving a misbranding charge that stems from off-label marketing, FDA and the Department of Justice argue that once a manufacturer promotes a drug, whether through oral or written statements, for an unapproved use, such use becomes an "intended" use such that the label no longer accurately conveys "adequate directions for use," rendering the product misbranded. Over the years, the ban on off-label communications has become broadly applied by the government and has stifled drug company's engagement with new communication tools, for example social media and other types of electronic communications.

Factual Background 

Amarin's drug Vescepa (icosapent ethyl) was approved for use in adults with very high levels of triglycerides, and Amarin subsequently sought approval to market Vascepa for a second use, in patients with "persistently high triglycerides." Amarin completed a clinical study for this second use, but FDA did not grant approval for the proposed indication, based on the fact that there was uncertainty regarding the impact of the triglyceride reductions in those patients' cardiovascular risk profiles (notwithstanding that Amarin had met its study objectives and Vascepa produced a statistically significant reduction in those patients' triglyceride levels). This second use is the off-label use at issue in the case, for which Amarin wanted to make certain objectively truthful statements to doctors, including about the results of the clinical trial conducted in patients with persistently high triglycerides.

When FDA denied approval of Amarin's application for the second indication, the letter also stated that Vascepa may be considered misbranded under the FFDCA if it is marketed with a discussion of the study results "before approval of this supplemental application" (such warnings about potential violations of the Act are common language in certain Agency communications to drug sponsors). After receiving FDA's letter, Amarin, along with several physicians, brought an as-applied First Amendment challenge to FDA's policy prohibiting Amarin "from making completely truthful and non-misleading statements about its product to sophisticated healthcare professionals."

Amarin's complaint also contended that FDA's position deprived the physician co-plaintiffs of important medical information, because physicians may lawfully prescribe drugs for off-label uses and, indeed, in many contexts off-label use may be the standard of care (to the extent that Medicare and other payors may cover payment for such uses). Amarin alleged that physicians "need truthful and non-misleading information about these drugs to make informed decisions about what is best for their patients," but FDA's "current regime for regulating the flow of 'off-label' information. . . severely restricts medical professionals' access to information from the source most knowledgeable about the drugs: the drug manufacturers."

In addition to the broad speech protection that Amarin sought to obtain, the company also sought a ruling permitting it to make specific statements that it alleged were "carefully-circumscribed, truthful, and scientifically-accurate," and it provided specific off-label promotional content regarding Vascepa for the court's review. After filing the complaint, Amarin sought a preliminary injunction to prevent FDA from bringing a misbranding action, with the Agency's written enforcement threat as a factor weighing in Amarin's favor.

Court Grants Preliminary Injunction Request

In his August 7 ruling, District Judge Engelmayer sided with Amarin, explaining that the court's "considered and firm view is that, under Caronia, the FDA may not bring such an action based on truthful promotional speech alone, consistent with the First Amendment." The court held that under Caronia, truthful and non-misleading speech promoting the off-label use of an FDA-approved drug cannot be the basis for a misbranding action.

Next, the court analyzed Amarin's specific proposed statements about Vascepa, which consisted of three specific statements regarding the second, unapproved use of Vascepa; five disclosures to assure its statements were not misleading; and several scientific reprints that the company proposed to disseminate.

  • Discussion of the clinical study – The court found Amarin's proposed discussion of a clinical study "studiously neutral" and held that Amarin's dissemination of this summary was neither false nor misleading (which FDA did not dispute)
  • Disclosures – FDA contested two disclosures that would accompany Amarin's proposed off-label promotion. The court proposed amendments to the disclosures, and held, with the revisions, the disclosures were "at present, truthful and non-misleading."
  • Reprints – The court decided (and FDA did not dispute) that Amarin's dissemination of certain proposed reprints, under the circumstances proposed, would be neither false nor misleading.


Judge Engelmayer's ruling is quite detailed and thorough, especially for a preliminary injunction, which may indicate that he expects FDA to appeal the First Amendment holding against it (the Agency did not seek any review of the Second Circuit's Caronia decision). So we will continue to monitor and report on any developments in this case.

There are several factors that mark this ruling as only the beginning of a transformation in the area of drug manufacturer communications and FDA regulation.

  • The court scrutinized the accuracy of Amarin's specific proposed statements and disclosures in light of an extensive FDA record, including communications between the company and the agency about clinical data. As a result, that portion of the court's analysis may have limited application where a manufacturer does not have a similarly detailed FDA regulatory history.
  • Vascepa has an unusually favorable safety profile and, indeed, the court found FDA's public safety arguments against off-label promotion for this specific product to be unconvincing. Drugs with more significant side effects and warnings in the labeling may have more difficulty presenting all material facts in way that satisfies all interests.
  • The accuracy of Amarin's off-label claims could be achieved through the use of appropriate disclaimer language, a less burdensome means than a complete ban by FDA on the speech in question.  In factually different circumstances, however, use of a disclaimer may not be sufficient to cure potentially misleading off-label promotion of a drug or it may be difficult to determine when a claim is misleading. Indeed, the court pointed out that it can be difficult to determine when information is "one-sided" or "incomplete."

So it is important to remember that neither the court's decision here nor the First Amendment more generally would protect a manufacturer from prosecution when it makes false, misleading, or unsubstantiated claims about a drug product. We expect other companies to also seek constitutional protection for specific off-label marketing campaigns from the courts until FDA revises its policies in this area – or until a favorable decision from the Supreme Court applies broadly to all members of regulated industry.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions